In vivo CAR-T engineering: insights from the 2025 ASH annual meeting
Abstract In vivo chimeric antigen receptor (CAR)-T engineering is a prominent field of research in cancer immunology, in which vectors are used to reprogram endogenous T-cells into CAR-T cells. Viral and nonviral platforms presented at the 67th Annual Meeting of the American Society of Hematology (A...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2026-02-01
|
| シリーズ: | Experimental Hematology & Oncology |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s40164-026-00762-8 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|